Ignite Creation Date:
2024-05-06 @ 5:10 PM
Last Modification Date:
2024-10-26 @ 2:23 PM
Study NCT ID:
NCT05216432
Status:
RECRUITING
Last Update Posted:
2024-06-06
First Post:
2021-12-20
Brief Title:
First-in-Human Study of Mutant-selective PI3Kα Inhibitor RLY-2608 As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
Sponsor:
Relay Therapeutics Inc
Organization:
Relay Therapeutics Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| PIK3CA Mutation |
| Solid Tumor Adult |
| HER2-negative Breast Cancer |
| Breast Cancer |
| Metastatic Breast Cancer |
| Advanced Breast Cancer |
| Unresectable Solid Tumor |
Keywords: